Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2001 Jan;84(1):76–81. doi: 10.1136/adc.84.1.76

A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis

D Johnston 1, P Betts 1, D Dunger 1, N Barnes 1, P Swift 1, J Buckler 1, G Butler 1
PMCID: PMC1718629  PMID: 11124794

Abstract

BACKGROUND—Turner syndrome accounts for 15-20% of childhood usage of growth hormone (GH) in the UK but final height benefit remains uncertain. The most effective strategy for oestrogen replacement is also unclear.
METHODS—Fifty eight girls who, at start of treatment, were of mean age 9.1 years and projected final height 142.2 cm were randomised to receive in year 1, either low dose ethinyloestradiol 50-75 ng/kg/day, GH 28 IU/m2 surface area/week as a daily injection, or a combination of ethinyloestradiol and GH. After the first year, the ethinyloestradiol treated girls received combination treatment. After two years, girls aged over 12 years were given escalating ethinyloestradiol to promote pubertal development.
RESULTS—Near final height was available for 49 girls at age 16.5 years, 146.8 cm, representing a gain of 4.6 cm, range −7.9 to +11.7 cm. Twelve of the 49 girls gaining 7.5 cm or more were less than 13 years at the start and had received GH for at least four years. Height gain was correlated with greater initial height deficit. Fifteen girls (31%) reached 150 cm or more compared to a predicted 10%. Early supplementation with ethinyloestradiol provided no final height advantage.
CONCLUSIONS—Final height gain was modest at 4.6 cm. Younger, shorter girls gained greatest height advantage from GH. Low dosage ethinyloestradiol before planned induction of puberty was not beneficial.



Full Text

The Full Text of this article is available as a PDF (142.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckett P. R., Copeland K. C., Flannery T. K., Sherman L. D., Abrams S. A. Combination growth hormone and estrogen increase bone mineralization in girls with Turner syndrome. Pediatr Res. 1999 May;45(5 Pt 1):709–713. doi: 10.1203/00006450-199905010-00017. [DOI] [PubMed] [Google Scholar]
  2. Betts P. R., Butler G. E., Donaldson M. D., Dunger D. B., Johnston D. I., Kelnar C. J., Kirk J., Price D. A., Wilton P. A decade of growth hormone treatment in girls with Turner syndrome in the UK. UK KIGS Executive Group. Arch Dis Child. 1999 Mar;80(3):221–225. doi: 10.1136/adc.80.3.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chernausek S. D., Attie K. M., Cara J. F., Rosenfeld R. G., Frane J. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. J Clin Endocrinol Metab. 2000 Jul;85(7):2439–2445. doi: 10.1210/jcem.85.7.6684. [DOI] [PubMed] [Google Scholar]
  4. Donaldson M. D. Growth hormone therapy in Turner syndrome--current uncertainties and future strategies. Horm Res. 1997;48 (Suppl 5):35–44. doi: 10.1159/000191327. [DOI] [PubMed] [Google Scholar]
  5. Freeman J. V., Cole T. J., Chinn S., Jones P. R., White E. M., Preece M. A. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child. 1995 Jul;73(1):17–24. doi: 10.1136/adc.73.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hofman P., Cutfield W. S., Robinson E. M., Clavano A., Ambler G. R., Cowell C. Factors predictive of response to growth hormone therapy in Turner's syndrome. J Pediatr Endocrinol Metab. 1997 Jan-Feb;10(1):27–33. doi: 10.1515/jpem.1997.10.1.27. [DOI] [PubMed] [Google Scholar]
  7. Lyon A. J., Preece M. A., Grant D. B. Growth curve for girls with Turner syndrome. Arch Dis Child. 1985 Oct;60(10):932–935. doi: 10.1136/adc.60.10.932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Massa G., Otten B. J., de Muinck Keizer-Schrama S. M., Delemarre-van de Waal H. A., Jansen M., Vulsma T., Oostdijk W., Waelkens J. J., Wit J. M. Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. Dutch Growth Hormone Working Group. Horm Res. 1995;43(4):144–146. doi: 10.1159/000184262. [DOI] [PubMed] [Google Scholar]
  9. Nilsson K. O., Albertsson-Wikland K., Alm J., Aronson S., Gustafsson J., Hagenäs L., Häger A., Ivarsson S. A., Karlberg J., Kriström B. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab. 1996 Feb;81(2):635–640. doi: 10.1210/jcem.81.2.8636281. [DOI] [PubMed] [Google Scholar]
  10. Rosenfeld R. G., Attie K. M., Frane J., Brasel J. A., Burstein S., Cara J. F., Chernausek S., Gotlin R. W., Kuntze J., Lippe B. M. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr. 1998 Feb;132(2):319–324. doi: 10.1016/s0022-3476(98)70452-4. [DOI] [PubMed] [Google Scholar]
  11. Rosenfeld R. G., Hintz R. L., Johanson A. J., Sherman B., Brasel J. A., Burstein S., Chernausek S., Compton P., Frane J., Gotlin R. W. Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome. J Pediatr. 1988 Aug;113(2):393–400. doi: 10.1016/s0022-3476(88)80290-7. [DOI] [PubMed] [Google Scholar]
  12. Ross J. L., Cassorla F. G., Skerda M. C., Valk I. M., Loriaux D. L., Cutler G. B., Jr A preliminary study of the effect of estrogen dose on growth in Turner's syndrome. N Engl J Med. 1983 Nov 3;309(18):1104–1106. doi: 10.1056/NEJM198311033091806. [DOI] [PubMed] [Google Scholar]
  13. Sas T. C., de Muinck Keizer-Schrama S. M., Stijnen T., Aanstoot H. J., Drop S. L. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab. 2000 Feb;85(2):769–775. doi: 10.1210/jcem.85.2.6334. [DOI] [PubMed] [Google Scholar]
  14. Sas T. C., de Muinck Keizer-Schrama S. M., Stijnen T., Jansen M., Otten B. J., Hoorweg-Nijman J. J., Vulsma T., Massa G. G., Rouwe C. W., Reeser H. M. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999 Dec;84(12):4607–4612. doi: 10.1210/jcem.84.12.6241. [DOI] [PubMed] [Google Scholar]
  15. Tsezou A., Hadjiathanasiou C., Gourgiotis D., Galla A., Kavazarakis E., Pasparaki A., Kapsetaki M., Sismani C., Theodoridis C., Patsalis P. C. Molecular genetics of Turner syndrome: correlation with clinical phenotype and response to growth hormone therapy. Clin Genet. 1999 Dec;56(6):441–446. doi: 10.1034/j.1399-0004.1999.560606.x. [DOI] [PubMed] [Google Scholar]
  16. de Muinck Keizer-Schrama S. M., Sas T. C. Growth hormone treatment regimens in girls with Turner syndrome. Dutch Advisory Group on Growth Hormone. Acta Paediatr Suppl. 1999 Dec;88(433):126–129. doi: 10.1111/j.1651-2227.1999.tb14421.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES